L. Pusztai

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
L Pusztai, L. Pusztai, Lajos Pusztai, Lajos Pusztai Pusztai
Publication record
902 papers · 58,079 citations · H-index 110

PAPERS

Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomes.
20241 citationsauthor #13
Dynamic clustering of genomics cohorts beyond race, ethnicity—and ancestry
20242 citationsauthor #6
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
20237 citationsauthor #11
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
202313 citationsauthor #19
ASO Author Reflections: Immunotherapy and Breast Cancer-Spotlight on Early Stage TNBC.
20230 citationsauthor #2
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
20230 citationsauthor #6
Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Cancer (MBC)
20230 citationsauthor #13
Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
20236 citationsauthor #9
ASO Visual Abstract: Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancers-Catching up with the Rest.
20230 citationsauthor #3
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
202327 citationsauthor #13
Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history.
20230 citationsauthor #7
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
202343 citationsauthor #89
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?
20230 citationsauthor #3
Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814
20231 citationsauthor #12
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
202312 citationsauthor #8
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
20230 citationsauthor #11
Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
20230 citationsauthor #5
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer
202312 citationsauthor #10
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
202313 citationsauthor #19
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
20236 citationsauthor #7
Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents
20230 citationsauthor #15
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
20237 citationsauthor #3
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
20230 citationsauthor #9
Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®
20230 citationsauthor #9
Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER)
20231 citationsauthor #5
Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
20232 citationsauthor #19
Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
20237 citationsauthor #4
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
20237 citationsauthor #3
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
202342 citationsauthor #95
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
202349 citationsauthor #13
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
20236 citationsauthor #11
Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
20233 citationsauthor #1
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
202358 citationsauthor #19
University of Birmingham Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer
20230 citationsauthor #99
Abstract P4-09-05: Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials
20230 citationsauthor #12
More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome
202316 citationsauthor #12
Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers
20230 citationsauthor #11
Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)
202311 citationsauthor #22
Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing
20235 citationsauthor #8
Trends in breast cancer death by stage at diagnoses in 2000-2018.
20231 citationsauthor #11
Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status
20230 citationsauthor #19
Abstract OT2-01-04: ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
20233 citationsauthor #2
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
20234 citationsauthor #9
Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
20232 citationsauthor #3
De Novo Oligometastatic Breast Cancer.
20239 citationsauthor #1
BPI23-012: Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 Therapy Related Cardiac Events in HER2+ Breast Cancer Patients
20230 citationsauthor #4
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
20234 citationsauthor #11
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
20235 citationsauthor #5
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
20230 citationsauthor #13
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
202316 citationsauthor #12
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
202321 citationsauthor #6
Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC
20230 citationsauthor #6
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
20239 citationsauthor #16
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
202314 citationsauthor #5
Abstract P2-11-11: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study
20230 citationsauthor #11
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226.
20230 citationsauthor #11
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
202358 citationsauthor #3
Abstract PR009: Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome
20232 citationsauthor #10
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
202216 citationsauthor #15
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
20224 citationsauthor #7
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
20223 citationsauthor #21
Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.
20220 citationsauthor #10
Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.
202225 citationsauthor #20
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
20226 citationsauthor #14
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
2022765 citationsauthor #4
Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes
20221 citationsauthor #9
Abstract P1-02-02: Examination of low Her2 expression in breast cancer
20220 citationsauthor #21
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
202211 citationsauthor #6
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
202275 citationsauthor #9
Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial
20221 citationsauthor #11
Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study
20220 citationsauthor #4
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
20220 citationsauthor #5
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
20220 citationsauthor #8
Analysis by residual cancer burden further clarifies effect of pembrolizumab
20220 citationsauthor #1
Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.
20221 citationsauthor #6
Abstract P5-08-16: MTAP deletion and synthetic lethality-based drug development for metastatic breast cancer (MBC)
20220 citationsauthor #1
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
2022280 citationsauthor #21
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
20220 citationsauthor #21
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup
20220 citationsauthor #4
Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors
20221 citationsauthor #6
Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial
20220 citationsauthor #13
Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes
20220 citationsauthor #8
The effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer settings.
20221 citationsauthor #1
Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.
20220 citationsauthor #14
Intratumour heterogeneity, from hypothesis to the clinic
20221 citationsauthor #3
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
202240 citationsauthor #9
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
20228 citationsauthor #3
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
20229 citationsauthor #4
139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
20220 citationsauthor #12
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
2022105 citationsauthor #20
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
20222 citationsauthor #8
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
20220 citationsauthor #7
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
202215 citationsauthor #9
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
2022249 citationsauthor #13
Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer
20220 citationsauthor #11
Comprehensive analysis of metabolic isozyme targets in cancer.
202210 citationsauthor #17
MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTS
20220 citationsauthor #8
Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
20226 citationsauthor #10
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
202225 citationsauthor #11
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
202214 citationsauthor #15

TIMELINE

1993 11 citations

1994 86 citations

1996 58 citations

1998 137 citations

1999 52 citations

2000 5 citations

2001 299 citations

2002 679 citations

2003 1,965 citations

2004 2,908 citations

2005 4,395 citations

2006 1,708 citations

2007 2,516 citations

2008 4,881 citations

2009 2,735 citations

2010 3,489 citations

2011 3,214 citations

2012 3,840 citations

2013 3,884 citations

2014 3,533 citations

2015 1,774 citations

2016 2,859 citations

2017 1,996 citations

2018 1,312 citations

2019 1,036 citations

2020 3,991 citations

2021 2,156 citations

2022 2,019 citations

2023 502 citations

2024 3 citations

L. Pusztai

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT